Argent BioPharma Enters Germany - Europe's Largest Market

2 days ago

PR Newswire

PERTH, Australia, April 23, 2025

Strategic Expansion Paired with Over $1M in Annual Cost Savings from Operational Restructuring

PERTH, Australia, April 23, 2025 /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company specializing in neuroimmune therapies, is pleased to announce its official entry into the German pharmaceutical market with the receipt of initial purchase orders for CannEpil® and CogniCann®, following recent regulatory approval. Germany, as the largest healthcare market in Europe, represents a significant commercial milestone and a strategic beachhead for Argent's broader European expansion.

In parallel, the Company has successfully completed the transfer of its EU GMP-certified manufacturing facilities in Slovenia and Malta to trusted third-party operators. This strategic operational shift allows Argent to maintain GMP compliance while reducing infrastructure overhead, resulting in annual operational cost savings exceeding USD $1 million. These efficiencies free up capital to further accelerate R&D initiatives and clinical trials across core therapeutic programs.

These achievements reflect Argent BioPharma's broader transformation strategy—centered on fully proprietary, neuroimmune drug development, in-house innovation, and sustainable global scalability. The Company remains focused on advancing its therapeutic pipeline while deepening market penetration across high-value regions.

About Argent BioPharma
Argent BioPharma Ltd. (ASX: RGT) develops proprietary therapeutics targeting central nervous system (CNS) and autoimmune disorders using its Neuro-Immune Modulatory (NIM) platform. Lead assets include CannEpil®, CogniCann®, and CimetrA®, which are now entering major European markets as part of a targeted international growth plan.

Contact:
Roby Zomer
CEO & Managing Director
+61 8 6555 2950
[email protected]

Rowan Harland
Company Secretary
+61 8 6555 2950
[email protected]

View original content:https://www.prnewswire.com/news-releases/argent-biopharma-enters-germany--europes-largest-market-302435972.html

SOURCE Argent BioPharma Ltd.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.